Literature DB >> 7748522

Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue.

L O Hansson1, N Waters, B Winblad, C G Gottfries, A Carlsson.   

Abstract

A previously performed post-mortem study comparing monoaminergic indices in the brains of 14 schizophrenic patients and 10 patients with psychosis not diagnosed as schizophrenia, with age-matched control cases without any known neuropsychiatric illness, was re-investigated, using multivariate analysis. The monoaminergic patterns showing up in this analysis suggested the existence of at least two different forms of the disease, both of which could be distinguished from the controls as well as from each other. One of the schizophrenic groups consisted of paranoid cases, and had a relatively mild family history, whereas the other group, mainly consisting of hebephrenic cases, had a severe family history. The former group showed low levels of dopamine and high levels of serotonergic precursor and metabolite, whereas the latter group in some respects tended to show the opposite aberrations. Neuroleptic treatment did not seem to account for the different biochemical profiles, unless one assumes that this treatment can cause completely different monoaminergic aberrations in different individuals. Instead, one could argue that the different biochemical profiles found are characteristic of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7748522     DOI: 10.1007/BF01276538

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  16 in total

Review 1.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

Authors:  M Carlsson; A Carlsson
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

2.  Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

Authors:  M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga
Journal:  Acta Psychiatr Scand       Date:  1988-08       Impact factor: 6.392

3.  Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and homovanillic acid in brain tissue from an autopsy material.

Authors:  C G Gottfries; B E Roos; B Winblad
Journal:  Acta Psychiatr Scand       Date:  1974       Impact factor: 6.392

4.  A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using a single column of strongly acidic cation exchange resin.

Authors:  C Atack; T Magnusson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-01

5.  Classification of human cancer cells by means of capillary gas chromatography and pattern recognition analysis.

Authors:  E Jellum; I Bjørnson; R Nesbakken; E Johansson; S Wold
Journal:  J Chromatogr       Date:  1981-11-06

6.  Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group.

Authors:  J Beskow; C G Gottfries; B E Roos; B Winblad
Journal:  Acta Psychiatr Scand       Date:  1976-01       Impact factor: 6.392

Review 7.  Neurochemistry and neuroendocrinology of schizophrenia: a selective review.

Authors:  J A Lieberman; A R Koreen
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

8.  Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain.

Authors:  I J Farley; K S Price; E McCullough; J H Deck; W Hordynski; O Hornykiewicz
Journal:  Science       Date:  1978-04-28       Impact factor: 47.728

9.  Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls.

Authors:  W F Gattaz; T Gasser; H Beckmann
Journal:  Biol Psychiatry       Date:  1985-04       Impact factor: 13.382

10.  Monoamines and monoamine metabolites in brains from demented schizophrenics.

Authors:  B Winblad; G Bucht; C G Gottfries; B E Roos
Journal:  Acta Psychiatr Scand       Date:  1979-07       Impact factor: 6.392

View more
  5 in total

1.  5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.

Authors:  R A Padich; T C McCloskey; J H Kehne
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).

Authors:  P Martin; N Waters; A Carlsson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755.

Authors:  N Waters; C Lundgren; L O Hansson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.

Authors:  Ilona Klejbor; Aaron Kucinski; Scott R Wersinger; Thomas Corso; Jan H Spodnik; Jerzy Dziewiatkowski; Janusz Moryś; Renae A Hesse; Kenner C Rice; Robert Miletich; Ewa K Stachowiak; Michal K Stachowiak
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

5.  A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity.

Authors:  Göran Starck; Maria Ljungberg; Marie Nilsson; Lars Jönsson; Stefan Lundberg; Tord Ivarsson; Susanne Ribbelin; Sven Ekholm; Arvid Carlsson; Eva Forssell-Aronsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.